Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.54)
# 2,144
Out of 5,154 analysts
144
Total ratings
54.44%
Success rate
-1.38%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XRAY DENTSPLY SIRONA | Maintains: In-Line | $12 → $15 | $12.74 | +17.74% | 9 | Feb 27, 2026 | |
| TDOC Teladoc Health | Maintains: In-Line | $8 → $5 | $5.08 | -1.57% | 7 | Feb 26, 2026 | |
| MDLN Medline | Maintains: Outperform | $50 → $55 | $43.83 | +25.48% | 2 | Feb 26, 2026 | |
| HSIC Henry Schein | Maintains: Outperform | $90 → $100 | $77.60 | +28.87% | 3 | Feb 25, 2026 | |
| WAY Waystar Holding | Maintains: Outperform | $40 → $27 | $25.71 | +5.02% | 5 | Feb 18, 2026 | |
| HNGE Hinge Health | Maintains: Outperform | $65 → $50 | $46.14 | +8.37% | 3 | Feb 11, 2026 | |
| DGX Quest Diagnostics | Maintains: In-Line | $190 → $220 | $199.21 | +10.44% | 5 | Feb 11, 2026 | |
| ALGN Align Technology | Maintains: Outperform | $180 → $200 | $174.00 | +14.94% | 16 | Feb 5, 2026 | |
| FTRE Fortrea Holdings | Upgrades: Outperform | $14 → $25 | $9.61 | +160.15% | 11 | Jan 6, 2026 | |
| PRVA Privia Health Group | Maintains: Outperform | $28 → $30 | $23.27 | +28.92% | 5 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $28 | $14.05 | +99.29% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $70 | $25.34 | +176.24% | 10 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $220 | $217.78 | +1.02% | 10 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $95 | $77.92 | +21.92% | 10 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $220 → $240 | $174.49 | +37.54% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $4 → $3 | $1.95 | +53.85% | 9 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $300 → $305 | $269.67 | +13.10% | 7 | Oct 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $800 → $825 | $919.26 | -10.25% | 7 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $23 | $26.86 | -14.37% | 4 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $5 → $3 | $0.60 | +401.42% | 5 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $1.72 | +1,426.16% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $1.64 | +814.63% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $0.76 | +1,356.76% | 2 | Jan 4, 2022 |
DENTSPLY SIRONA
Feb 27, 2026
Maintains: In-Line
Price Target: $12 → $15
Current: $12.74
Upside: +17.74%
Teladoc Health
Feb 26, 2026
Maintains: In-Line
Price Target: $8 → $5
Current: $5.08
Upside: -1.57%
Medline
Feb 26, 2026
Maintains: Outperform
Price Target: $50 → $55
Current: $43.83
Upside: +25.48%
Henry Schein
Feb 25, 2026
Maintains: Outperform
Price Target: $90 → $100
Current: $77.60
Upside: +28.87%
Waystar Holding
Feb 18, 2026
Maintains: Outperform
Price Target: $40 → $27
Current: $25.71
Upside: +5.02%
Hinge Health
Feb 11, 2026
Maintains: Outperform
Price Target: $65 → $50
Current: $46.14
Upside: +8.37%
Quest Diagnostics
Feb 11, 2026
Maintains: In-Line
Price Target: $190 → $220
Current: $199.21
Upside: +10.44%
Align Technology
Feb 5, 2026
Maintains: Outperform
Price Target: $180 → $200
Current: $174.00
Upside: +14.94%
Fortrea Holdings
Jan 6, 2026
Upgrades: Outperform
Price Target: $14 → $25
Current: $9.61
Upside: +160.15%
Privia Health Group
Nov 7, 2025
Maintains: Outperform
Price Target: $28 → $30
Current: $23.27
Upside: +28.92%
Nov 7, 2025
Maintains: Outperform
Price Target: $27 → $28
Current: $14.05
Upside: +99.29%
Nov 7, 2025
Maintains: Outperform
Price Target: $81 → $70
Current: $25.34
Upside: +176.24%
Oct 31, 2025
Maintains: Outperform
Price Target: $190 → $220
Current: $217.78
Upside: +1.02%
Oct 30, 2025
Maintains: Outperform
Price Target: $85 → $95
Current: $77.92
Upside: +21.92%
Oct 8, 2025
Maintains: Outperform
Price Target: $220 → $240
Current: $174.49
Upside: +37.54%
Oct 8, 2025
Maintains: In-Line
Price Target: $4 → $3
Current: $1.95
Upside: +53.85%
Oct 3, 2025
Maintains: Outperform
Price Target: $300 → $305
Current: $269.67
Upside: +13.10%
Sep 24, 2025
Maintains: Outperform
Price Target: $800 → $825
Current: $919.26
Upside: -10.25%
Jul 9, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $26.86
Upside: -14.37%
Jul 9, 2025
Maintains: In-Line
Price Target: $5 → $3
Current: $0.60
Upside: +401.42%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $1.72
Upside: +1,426.16%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $1.64
Upside: +814.63%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $0.76
Upside: +1,356.76%